Literature DB >> 12719581

Role of the serine-threonine kinase PAK-1 in myxoma virus replication.

J B Johnston1, John W Barrett, Wen Chang, Che-Sheng Chung, Wei Zeng, Jennefer Masters, Melissa Mann, Fuan Wang, Jingxin Cao, Grant McFadden.   

Abstract

Subversion or appropriation of cellular signal transduction pathways is a common strategy employed by viruses to promote an environment within infected cells that supports the viral replicative cycle. Using subsets of 3T3 murine fibroblasts previously shown to differ in their ability to support myxoma virus (MV) replication, we investigated the role of host serine-threonine kinases (STKs) as potential mediators of the permissive phenotype. Both permissive and nonpermissive 3T3 cells supported equivalent levels of virion binding, entry, and early virus gene expression, indicating that MV tropism in 3T3 cells was not determined by receptor-mediated entry. In contrast, late virus gene expression and viral DNA replication were selectively compromised in restrictive 3T3 cells. Addition of specific protein kinase inhibitors, many of which shared the ability to influence the activity of the STKs p21-activated kinase 1 (PAK-1) and Raf-1 attenuated MV replication in permissive 3T3 cells. Western blot detection of the phosphorylated forms of PAK-1 (Thr423) and Raf-1 (Ser338) confirmed activation of these kinases in permissive cells after MV infection or gamma interferon treatment, but the activated forms of both kinases were greatly reduced or absent in restrictive 3T3 cells. The biological significance of these activations was demonstrated by using the autoinhibitory domain of PAK-1 (amino acids 83 to 149), expression of which reduced the efficiency of MV infection in permissive 3T3 cells concurrent with a decrease in PAK-1 activation. In comparison, overexpression of a constitutively active PAK-1 (T423E) mutant increased MV replication in restrictive 3T3 cells. These observations suggest that induced signaling via cellular STKs may play important roles in determining the permissiveness of host cells to poxvirus infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719581      PMCID: PMC154029          DOI: 10.1128/jvi.77.10.5877-5888.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Src kinases involved in hepatitis B virus replication.

Authors:  N P Klein; M J Bouchard; L H Wang; C Kobarg; R J Schneider
Journal:  EMBO J       Date:  1999-09-15       Impact factor: 11.598

2.  Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.

Authors:  E Tzahar; J D Moyer; H Waterman; E G Barbacci; J Bao; G Levkowitz; M Shelly; S Strano; R Pinkas-Kramarski; J H Pierce; G C Andrews; Y Yarden
Journal:  EMBO J       Date:  1998-10-15       Impact factor: 11.598

3.  Compact, synthetic, vaccinia virus early/late promoter for protein expression.

Authors:  S Chakrabarti; J R Sisler; B Moss
Journal:  Biotechniques       Date:  1997-12       Impact factor: 1.993

4.  Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent.

Authors:  M Sakatsume; L F Stancato; M David; O Silvennoinen; P Saharinen; J Pierce; A C Larner; D S Finbloom
Journal:  J Biol Chem       Date:  1998-01-30       Impact factor: 5.157

Review 5.  Viral strategies of immune evasion.

Authors:  H L Ploegh
Journal:  Science       Date:  1998-04-10       Impact factor: 47.728

6.  The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner.

Authors:  K Xia; N K Mukhopadhyay; R C Inhorn; D L Barber; P E Rose; R S Lee; R P Narsimhan; A D D'Andrea; J D Griffin; T M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling.

Authors:  F Frischknecht; V Moreau; S Röttger; S Gonfloni; I Reckmann; G Superti-Furga; M Way
Journal:  Nature       Date:  1999-10-28       Impact factor: 49.962

8.  A third distinct tumor necrosis factor receptor of orthopoxviruses.

Authors:  V N Loparev; J M Parsons; J C Knight; J F Panus; C A Ray; R M Buller; D J Pickup; J J Esposito
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

9.  The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus.

Authors:  J E Strong; M C Coffey; D Tang; P Sabinin; P W Lee
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

10.  Activation of Raf-1 by interferon gamma and oncostatin M requires expression of the Stat1 transcription factor.

Authors:  L F Stancato; C R Yu; E F Petricoin; A C Larner
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

View more
  50 in total

1.  The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication.

Authors:  Anderson A Andrade; Patrícia N G Silva; Anna C T C Pereira; Lirlândia P De Sousa; Paulo C P Ferreira; Ricardo T Gazzinelli; Erna G Kroon; Catherine Ropert; Cláudio A Bonjardim
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

2.  Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells.

Authors:  Nancy Y Villa; Eric Bartee; Mohamed R Mohamed; Masmudur M Rahman; John W Barrett; Grant McFadden
Journal:  Virology       Date:  2010-03-24       Impact factor: 3.616

3.  Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication.

Authors:  Ramtin Rahbar; Thomas T Murooka; Anna A Hinek; Carole L Galligan; Antonella Sassano; Celeste Yu; Kishore Srivastava; Leonidas C Platanias; Eleanor N Fish
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease.

Authors:  Jane C Burns; Chisato Shimizu; Enrique Gonzalez; Hemant Kulkarni; Sukeshi Patel; Hiroko Shike; Robert S Sundel; Jane W Newburger; Sunil K Ahuja
Journal:  J Infect Dis       Date:  2005-06-08       Impact factor: 5.226

5.  Role for CCR5 in dissemination of vaccinia virus in vivo.

Authors:  Ramtin Rahbar; Thomas T Murooka; Eleanor N Fish
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

6.  Current Status for High Titre Poxvirus Stock Preparation in CEF Under Serum-Free Medium Conditions: Implication for Vaccine Development.

Authors:  Philippe-Alexandre Gilbert; Lacrimioara Comanita; John Barrett; Andrew Peters; Marta Szabat; Grant McFadden; Gregory A Dekaban
Journal:  Cytotechnology       Date:  2005-06       Impact factor: 2.058

7.  The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status.

Authors:  M Kim; C T Williamson; J Prudhomme; D G Bebb; K Riabowol; P W K Lee; S P Lees-Miller; Y Mori; M M Rahman; G McFadden; R N Johnston
Journal:  Oncogene       Date:  2010-05-17       Impact factor: 9.867

8.  Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.

Authors:  Nancy Y Villa; Clive H Wasserfall; Amy M Meacham; Elizabeth Wise; Winnie Chan; John R Wingard; Grant McFadden; Christopher R Cogle
Journal:  Blood       Date:  2015-04-22       Impact factor: 22.113

9.  Myxoma and vaccinia viruses bind differentially to human leukocytes.

Authors:  Winnie M Chan; Eric C Bartee; Jan S Moreb; Ken Dower; John H Connor; Grant McFadden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

10.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Authors:  Marianne M Stanford; Mae Shaban; John W Barrett; Steven J Werden; Philippe-Alexandre Gilbert; Joe Bondy-Denomy; Lisa Mackenzie; Kevin C Graham; Ann F Chambers; Grant McFadden
Journal:  Mol Ther       Date:  2007-11-13       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.